Insider Selling: Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Sells $297,062.77 in Stock

Eliem Therapeutics, Inc. (NASDAQ:ELYM) EVP Valerie Morisset sold 42,377 shares of the company’s stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $7.01, for a total transaction of $297,062.77. Following the completion of the sale, the executive vice president now directly owns 252,306 shares in the company, valued at $1,768,665.06. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Valerie Morisset also recently made the following trade(s):

• On Thursday, July 11th, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.11, for a total transaction of $355,500.00.
• On Tuesday, July 9th, Valerie Morisset sold 5,931 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.66, for a total transaction of $39,500.46.
• On Friday, July 5th, Valerie Morisset sold 12,342 shares of Eliem Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $87,134.52.
• On Wednesday, July 3rd, Valerie Morisset sold 50,000 shares of Eliem Therapeutics stock. The shares were sold at an average price of $6.76, for a total transaction of $338,000.00.

Eliem Therapeutics Stock Performance

Shares of ELYM opened at $6.77 on Friday. Eliem Therapeutics, Inc. has a 52 week low of $2.35 and a 52 week high of $11.55. The firm has a market cap of $201.41 million, a P/E ratio of -12.77 and a beta of -0.33. The firm’s 50-day simple moving average is $7.69 and its 200 day simple moving average is $4.93.

Eliem Therapeutics (NASDAQ:ELYM) last announced its quarterly earnings results on Wednesday, May 15th. The company reported ($0.06) EPS for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Eliem Therapeutics stock. BML Capital Management LLC grew its holdings in shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 0.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,193,742 shares of the company’s stock after purchasing an additional 13,742 shares during the period. Eliem Therapeutics comprises 4.0% of BML Capital Management LLC’s holdings, making the stock its 7th largest holding. BML Capital Management LLC owned 7.91% of Eliem Therapeutics worth $6,011,000 as of its most recent SEC filing. 69.76% of the stock is owned by institutional investors.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.